A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data

BACKGROUND: Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy. METHODS: All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight I...

Descripción completa

Detalles Bibliográficos
Autores principales: Capetti, Amedeo F., Cossu, Maria Vittoria, Orofino, Giancarlo, Sterrantino, Gaetana, Cenderello, Giovanni, De Socio, Giuseppe V., Cattelan, Anna Maria, Soria, Alessandro, Rusconi, Stefano, Riccardi, Niccolò, Baldin, Gian Maria, Niero, Fosca P., Barbarini, Giorgio, Rizzardini, Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622573/
https://www.ncbi.nlm.nih.gov/pubmed/28964268
http://dx.doi.org/10.1186/s12879-017-2755-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622573/
https://www.ncbi.nlm.nih.gov/pubmed/28964268
http://dx.doi.org/10.1186/s12879-017-2755-4

Ejemplares similares